Exhibit 99.1
ImmunoGen Reports Recent Progress and Second Quarter 2021 Financial Results
Compelling Final Data from FORWARD II Study Combining Mirvetuximab Soravtansine with Avastin® in Recurrent Ovarian Cancer, Regardless of Platinum Status, Presented at ASCO
Top-line Data from Pivotal SORAYA Trial on Track for Q4 Release
Continued Progress in Ongoing MIRASOL, IMGN632, and IMGC936 Studies
Conference Call to be Held at 8:00 a.m. ET Today
Waltham, MA – July 30, 2021 – ImmunoGen Inc. (Nasdaq: IMGN), a leader in the expanding field of antibody-drug conjugates (ADCs) for the treatment of cancer, today reviewed recent progress in the business and reported financial results for the quarter ended June 30, 2021.
"With top-line data from our pivotal SORAYA trial on track for release in Q4, we have accelerated preparations for the BLA submission and commercial launch of mirvetuximab. In parallel, we continue to generate data that support mirvetuximab as the combination agent of choice for ovarian cancer patients," said Mark Enyedy, ImmunoGen's President and Chief Executive Officer. "At ASCO, we presented final data from our mirvetuximab plus Avastin® doublet, showing compelling and durable anti-tumor activity, with a 64% ORR, 11.8 month mDOR, and 10.6 month mPFS in patients with high FRα recurrent ovarian cancer, regardless of platinum status. We believe these data are highly encouraging, particularly given outcomes with available therapies in this setting. As we continue to accrue our confirmatory MIRASOL trial, we are working to establish mirvetuximab as the new standard of care in patients with high FRα ovarian cancer, who comprise roughly 40% of the market. To this end, this quarter we are initiating PICCOLO, a single-arm study of mirvetuximab monotherapy in recurrent platinum-sensitive ovarian cancer to support label expansion."
Enyedy added, "Beyond mirvetuximab, our IMGN632, IMGC936, and IMGN151 programs are progressing as anticipated. Patient accrual continues in our IMGN632 trials in BPDCN and AML, with data from our AML cohort expected at ASH next quarter. Our dose-escalation study of IMGC936 is enrolling in multiple solid tumor types and we are on track to file the IND for IMGN151 by year-end. With a focus on execution towards key inflection points, we look forward to transforming ImmunoGen into a fully integrated oncology company with the potential for two innovative ADCs on the market in 2022."
RECENT PROGRESS
| ● | Presented final data from the FORWARD II study evaluating mirvetuximab in combination with Avastin® (bevacizumab) in patients with medium and high folate receptor alpha (FRα)-expressing recurrent ovarian cancer for whom a non-platinum based combination regimen is appropriate at the 2021 American Society of Clinical Oncology (ASCO) Virtual Annual Meeting. |
| ● | Completed accrual in the pivotal SORAYA study and further enrolled patients in the confirmatory MIRASOL study for mirvetuximab. |
| ● | Supported enrollment of investigator-sponsored trials of mirvetuximab plus carboplatin in a single-arm study in the neoadjuvant setting and in a randomized study in patients with recurrent platinum-sensitive ovarian cancer. |
| ● | Advanced accrual in the pivotal 801 Phase 2 study of IMGN632 in frontline and relapsed/refractory (R/R) blastic plasmacytoid dendritic cell neoplasm (BPDCN). |
| ● | Escalated dosing in the Phase 1 study of IMGC936 in multiple solid tumor types. |
| ● | Progressed activities to support an investigational new drug (IND) application for IMGN151. |
ANTICIPATED UPCOMING EVENTS
| ● | Release top-line data from the pivotal SORAYA study in the fourth quarter of 2021 and submit the biologics license application (BLA) in the first quarter of 2022 to support potential accelerated approval in 2022. |
| ● | Generate top-line data for the confirmatory MIRASOL study in the third quarter of 2022. |
| ● | Enroll the first patient in PICCOLO, a single-arm study of mirvetuximab monotherapy in high FRα recurrent platinum-sensitive ovarian cancer, in the third quarter of 2021, designed to support potential label expansion. |
| ● | Present initial AML combination data for IMGN632 at the 2021 American Society of Hematology (ASH) Annual Meeting in December 2021. |
| ● | Complete dose-escalation in the Phase 1 study evaluating IMGC936, with initial data anticipated in early 2022. |
| ● | Submit the IND application for IMGN151 by the end of 2021. |
FINANCIAL RESULTS
Revenues for the quarter ended June 30, 2021 were $16.9 million, compared with $15.0 million for the quarter ended June 30, 2020, which consisted primarily of non-cash royalty revenues.
Operating expenses for the second quarter of 2021 were $44.3 million, compared with $33.4 million for the same quarter in 2020. The increase was largely driven by research and development expenses, which were $34.6 million for the second quarter of 2021, compared with $22.9 million for the second quarter of 2020. This increase was due to greater clinical trial expenses driven by costs related to the MIRASOL, SORAYA, and IMGC936 studies, greater personnel and temporary staffing costs, and higher external manufacturing costs and third-party service fees in support of commercial readiness. General and administrative expenses for the second quarter of 2021 were $9.7 million, compared to $9.8 million for the second quarter of 2020.
Net loss for the second quarter of 2021 was $30.7 million, or $0.15 per basic and diluted share, compared to a net loss of $24.3 million, or $0.14 per basic and diluted share, for the second quarter of 2020. Weighted average shares outstanding increased to 199.9 million for the 2021 period from 174.4 million in the prior year.
ImmunoGen had $239.5 million in cash and cash equivalents as of June 30, 2021, compared with $293.9 million as of December 31, 2020, and had $1.1 million of convertible debt outstanding as of June 30, 2021, compared with $2.1 million as of December 31, 2020. Cash used in operations was $88.5 million for the first six months of 2021, compared with cash used in operations of $56.5 million for the same period in 2020. Capital expenditures were $(0.9) million for the first six months of 2021, compared with net proceeds from the sale of equipment of $1.4 million for the first six months of 2020.
FINANCIAL GUIDANCE
ImmunoGen's financial guidance for 2021 remains unchanged:
| ● | revenues between $65 million and $75 million; |
| ● | operating expenses between $200 million and $210 million; and |
| ● | cash and cash equivalents at December 31, 2021 to be between $140 million and $150 million. |
ImmunoGen expects that its current cash will fund operations into the second half of 2022.
CONFERENCE CALL INFORMATION
ImmunoGen will hold a conference call today at 8:00 a.m. ET to discuss these results. To access the live call by phone, dial (877) 621-5803; the conference ID is 1789134. The call may also be accessed through the Investors and Media section of the Company's website, www.immunogen.com. Following the call, a replay will be available at the same location.
ABOUT IMMUNOGEN
ImmunoGen is developing the next generation of antibody-drug conjugates (ADCs) to improve outcomes for cancer patients. By generating targeted therapies with enhanced anti-tumor activity and favorable tolerability profiles, we aim to disrupt the progression of cancer and offer our patients more good days. We call this our commitment to TARGET A BETTER NOW™.
Learn more about who we are, what we do, and how we do it at www.immunogen.com.
Avastin®, Vidaza®, and Venclexta® are registered trademarks of their respective owners.
FORWARD-LOOKING STATEMENTS
This press release includes forward-looking statements based on management's current expectations. These statements include, but are not limited to, ImmunoGen's expectations related to: the Company's revenues and operating expenses for the twelve months ending December 31, 2021; its cash and cash equivalents as of December 31, 2021; how long its current cash will fund operations, the occurrence, timing, and outcome of potential preclinical, clinical, and regulatory events related to the Company's product candidates; and the presentation of preclinical and clinical data on the Company's product candidates. For these statements, ImmunoGen claims the protection of the safe harbor for forward-looking statements provided by the Private Securities Litigation Reform Act of 1995. Various factors could cause ImmunoGen's actual results to differ materially from those discussed or implied in the forward-looking statements, and you are cautioned not to place undue reliance on these forward-looking statements, which are current only as of the date of this release. Factors that could cause future results to differ materially from such expectations include, but are not limited to: the timing and outcome of the Company's preclinical and clinical development processes; the difficulties inherent in the development of novel pharmaceuticals, including uncertainties as to the timing, expense, and results of preclinical studies, clinical trials, and regulatory processes; the Company's ability to financially support its product programs; risks and uncertainties associated with the scale and duration of the COVID-19 pandemic and the resulting impact on ImmunoGen's industry and business; and other factors as set forth in the Company's Annual Report on Form 10-K filed with the Securities and Exchange Commission on March 1, 2021, and other reports filed with the Securities and Exchange Commission.
INVESTOR RELATIONS AND MEDIA CONTACTS
ImmunoGen
Courtney O'Konek
781-895-0600
courtney.okonek@immunogen.com
OR
FTI Consulting
Robert Stanislaro
212-850-5657
robert.stanislaro@fticonsulting.com
| | | | | |
SELECTED FINANCIAL INFORMATION | |||||
(in thousands, except per share amounts) | |||||
| | | | | |
CONDENSED CONSOLIDATED BALANCE SHEETS | |||||
(Unaudited) | |||||
| | | | | |
| June 30, | | December 31, | ||
| 2021 | | 2020 | ||
ASSETS | | | | ||
| | | | | |
Cash and cash equivalents | $ | 239,538 | | $ | 293,856 |
Other assets | | 61,908 | | | 61,216 |
| | | | | |
Total assets | $ | 301,446 | | $ | 355,072 |
| | | | | |
LIABILITIES AND SHAREHOLDERS' EQUITY | | | | | |
| | | | | |
Current portion of deferred revenue | $ | 53,792 | | $ | 29,249 |
Other current liabilities | | 66,527 | | | 93,074 |
Long-term portion of deferred revenue | | 55,480 | | | 80,860 |
Other long-term liabilities | | 57,182 | | | 62,319 |
Shareholders' equity | | 68,465 | | | 89,570 |
| | | | | |
Total liabilities and shareholders' equity | $ | 301,446 | | $ | 355,072 |
| | | | | | | | | | | | |
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS | ||||||||||||
(Unaudited) | ||||||||||||
| | | | | | | | | | | | |
| Three Months Ended | | Six Months Ended | |||||||||
| June 30, | | June 30, | |||||||||
| 2021 | | 2020 | | | 2021 | | 2020 | ||||
| | | | | | | | | | | | |
Revenues: | | | | | | | | | | | | |
Non-cash royalty revenue | $ | 16,690 | | $ | 14,075 | | | $ | 32,235 | | $ | 27,072 |
License and milestone fees | | 252 | | | 945 | | | | 409 | | | 1,228 |
Research and development support | | 6 | | | 5 | | | | 10 | | | 12 |
| | | | | | | | | | | | |
Total revenues | | 16,948 | | | 15,025 | | | | 32,654 | | | 28,312 |
| | | | | | | | | | | | |
Expenses: | | | | | | | | | | | | |
Research and development | | 34,589 | | | 22,921 | | | | 69,002 | | | 50,329 |
General and administrative | | 9,728 | | | 9,767 | | | | 19,937 | | | 18,631 |
Restructuring charge | | - | | | 699 | | | | - | | | 1,524 |
| | | | | | | | | | | | |
Total operating expenses | | 44,317 | | | 33,387 | | | | 88,939 | | | 70,484 |
| | | | | | | | | | | | |
Loss from operations | | (27,369) | | | (18,362) | | | | (56,285) | | | (42,172) |
| | | | | | | | | | | | |
Non-cash interest expense on liability related to sale of future royalty & convertible bonds | | (3,557) | | | (6,081) | | | | (8,201) | | | (11,783) |
Interest expense on convertible bonds | | (23) | | | (23) | | | | (47) | | | (47) |
Other income (loss), net | | 208 | | | 168 | | | | (259) | | | 616 |
| | | | | | | | | | | | |
Net loss | $ | (30,741) | | $ | (24,298) | | | $ | (64,792) | | $ | (53,386) |
| | | | | | | | | | | | |
Basic and diluted net loss per common share | $ | (0.15) | | $ | (0.14) | | | $ | (0.32) | | $ | (0.31) |
| | | | | | | | | | | | |
Basic and diluted weighted average common shares outstanding | | 199,890 | | | 174,354 | | | | 199,365 | | | 171,055 |
| | | | | | | | | | | | |